# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Zora Neale Hurston (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML040-SYN
- Date: 2026-04-06
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lorraine Abernathy-Osei, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review after starting dapagliflozin. **S**

## History of present illness

Ms. Hurston returns two weeks after starting dapagliflozin and atorvastatin. She is less breathless: she now climbs the stairs at the school without stopping, and her ankles no longer swell by evening. Her home blood pressure average this week is 134/82. She has had no lightheadedness, genital itching or burning on passing urine, and no muscle aches. She weighs herself each morning. Her SNAP benefits were approved, the patient assistance program shipped a 90-day supply of dapagliflozin, and the SHINE counselor helped her apply for Extra Help and the Medicare Savings Program. She can name the BE FAST signs and keeps the card by her telephone. **S**

| Element | Detail |
|---|---|
| Home blood pressure | Average 134/82 mmHg |
| Symptoms | Stairs at school without stopping; ankle swelling gone |
| Medicine effects | No lightheadedness, genital infection or muscle aches |
| Benefits | SNAP approved; Extra Help and Medicare Savings Program applications submitted |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling; breathless only on hurrying |
| Genitourinary | Negative | No genital itching or dysuria |
| Musculoskeletal | Negative | No muscle aches or cramps |

3 systems reviewed. **S**

## Current medications

- Amlodipine 5 mg oral tablet, one tablet every morning **S**
- Chlorthalidone 25 mg oral tablet, one-half tablet (12.5 mg) every morning **S**
- Dapagliflozin 10 mg oral tablet, one tablet daily; pause on days of vomiting, diarrhea or not eating or drinking **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**
- Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 134/82 mmHg; pulse 76 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 82.6 kg; BMI 30.3 kg/m². All vital signs are synthetic.

Sodium: 137 mmol/L; Potassium: 3.4 mmol/L (low); Creatinine: 0.98 mg/dL; eGFR (CKD-EPI 2021): 63 mL/min/1.73 m²; Glucose: 94 mg/dL; Magnesium: 1.8 mg/dL. All results are synthetic.

## Change since baseline

- Sodium: 140 mmol/L at baseline, 137 mmol/L at this visit **S**
- Potassium: 3.9 mmol/L at baseline, 3.4 mmol/L (low) at this visit **S**
- Creatinine: 0.88 mg/dL at baseline, 0.98 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 72 mL/min/1.73 m² at baseline, 63 mL/min/1.73 m² at this visit **S**
- Glucose: 96 mg/dL at baseline, 94 mg/dL at this visit **S**
- Magnesium: 2 mg/dL at baseline, 1.8 mg/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 134/82, pulse 76; weight 82.6 kg |
| Neck | Jugular venous pressure not raised |
| Cardiovascular | Regular rhythm; S4 |
| Extremities | No edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Hypertensive heart disease** (I11.0). Blood pressure 134/82 in the clinic and at home: better but above the 130/80 target. Potassium has fallen to 3.4 mmol/L on chlorthalidone. **S**
   - Add spironolactone 12.5 mg daily, as cardiology advised if blood pressure stayed above target or potassium fell; it lowers blood pressure, raises potassium and may help HFpEF.
   - Metabolic panel in one to two weeks at the clinic laboratory.
   - Foods with potassium she likes: greens, beans, sweet potatoes and bananas.
2. **Heart failure with preserved ejection fraction** (I50.32). Improving: NYHA class I to II, no edema, weight down 1.6 kg since intake. Creatinine 0.98 mg/dL, a small expected rise after dapagliflozin. **S**
   - Continue dapagliflozin and daily weights.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure in the clinic (seated, average of two readings, large cuff) | Every visit | Completed today | 134/82 mmHg |
| Examination | Out-of-office blood pressure (ambulatory at diagnosis; home readings when treatment changes) | At diagnosis and with each treatment change | Completed today | Home average 134/82 mmHg |
| Examination | Weight, volume status (jugular venous pressure, edema, lungs) and NYHA class | Every visit | Completed today | 82.6 kg; jugular venous pressure not raised; no edema; NYHA I to II |
| Laboratory | Metabolic panel (sodium, potassium, creatinine and eGFR) and magnesium | One to two weeks after starting or changing a diuretic, SGLT2 inhibitor or MRA; then every three to six months | Completed today | Two weeks after dapagliflozin: sodium 137, potassium 3.4 (low), creatinine 0.98 mg/dL (eGFR 63), magnesium 1.8 |
| Medication safety | SGLT2 inhibitor: genital infection, volume depletion and sick-day rules | Every visit | Completed today | No genital infection or lightheadedness; sick-day rules reviewed |
| Imaging | ECG and echocardiogram | At diagnosis; repeat only with unexplained clinical change | Not indicated | Diagnosis made two weeks ago; no clinical change |
| Survey | KCCQ-12 heart failure health status | At diagnosis, then every three to six months | Up to date | 54 at diagnosis; next at about three months |
| Laboratory | Lipid panel | Four to twelve weeks after starting a statin; then yearly | Up to date | Two weeks on atorvastatin; panel at the next visit |
| Self-management | Self-care: daily weights, less salt, sick-day rules and the BE FAST stroke signs | Every visit | Completed today | Weighs daily; less salt at the table; teaches back the BE FAST signs |
| Medication safety | Medicine costs and coverage (generics, 90-day fills, patient assistance, Extra Help, Medicare Savings Program) | Every visit | Completed today | Dapagliflozin 90-day supply from patient assistance; Extra Help and Medicare Savings Program applications submitted |
| Self-management | Food access | Every visit | Completed today | SNAP approved |

## Goal progress

- Blood pressure below 130/80 mmHg in the clinic and at home within six months. In progress; target 2026-06-01. **S**
- Breathlessness only on heavy exertion and a KCCQ-12 score at least 15 points higher within six months. In progress; target 2026-10-19. **S**
- Every medicine affordable: generic 90-day fills, patient assistance until drug coverage begins, Extra Help and the Medicare Savings Program. In progress; target 2026-06-01. **S**
- Enough food through the month. In progress; target 2026-06-01. **S**
- Know the BE FAST signs of stroke and call 911 at once if any appear. Outcome by 2026-04-06: She teaches back the signs and keeps the card by the telephone. **S**

## Medication changes

- Started: Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) daily **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022), American Heart Association, American College of Cardiology, and Heart Failure Society of America (Circulation 2022;145(18):e895-e1032)
- CMID: Clinical Monitoring Intelligence Database, hypertension and heart failure monographs (2026), Aether Forge
- Signs and Symptoms of Stroke (2026), Centers for Disease Control and Prevention
- Help with drug costs (Extra Help) (2026), Centers for Medicare & Medicaid Services (Medicare.gov)
- Medicare Savings Programs (2026), Centers for Medicare & Medicaid Services (Medicare.gov)
- SNAP Eligibility (2026), U.S. Department of Agriculture, Food and Nutrition Service

## Follow-up

- Metabolic panel in one to two weeks at the clinic laboratory. Review in eight weeks with a metabolic panel, lipid panel and the KCCQ-12. **S**
- Next scheduled visit 2026-06-01: eight-week review: blood pressure at home and in the clinic, potassium and kidney function, lipids, KCCQ-12 and drug coverage. **S**
